Harold Bernstein, Chief Medical Officer of Maze Therapeutics, sold 15,000 shares of the company’s stock on April 1, 2026, for a total of approximately $442,000 at a price of $29.46 per share. This transaction marked the complete liquidation of his direct ownership in the company, following the exercise and immediate sale of stock options. The sale was disclosed in a SEC Form 4 filing and executed under a Rule 10b5-1 trading plan, a strategy often used by insiders to ensure compliance with insider trading regulations. Bernstein’s decision to sell comes amid a period of market volatility for Maze Therapeutics. The stock reached a 52-week high of $53.65 in March 2026, driven by positive clinical trial data, but has since experienced a decline. The company, which operates in the biotechnology sector with a focus on renal and metabolic disorders, reported a net loss of $131.1 million in 2025 and currently generates no revenue. Investors are closely watching the progress of Maze’s lead kidney drug, MZE829, as it seeks federal approval. While the sale of all directly-held shares by a C-suite executive may raise questions, the use of a Rule 10b5-1 plan suggests a prearranged, non-discretionary transaction. Bernstein still holds over 237,000 stock options, indicating continued alignment with the company’s long-term performance. The move, however, may influence investor sentiment, particularly in a market where high-risk biotech investments are sensitive to insider actions. Analysts caution that Maze Therapeutics remains a speculative bet, with its future dependent on regulatory outcomes and clinical success. The company’s recent stock price decline has created uncertainty, and investors are advised to carefully assess the risks associated with its pipeline and financial position.
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.